In non-glioma settings, MUC1-C has been associated with metabolic reprogramming in esophageal squamous cell carcinoma (ESCC) via the inhibition of the AKT pathway, making MUC-1 a potential target for treating ESCC [70]. Here, MUC1 is linked to central nervous system cancer.